The present invention relates to phenylsulfonylureas and phenylsulfonylthioureas, wherein the phenyl ring is substituted with a monovalent group comprising either (i) an aryl or a heteroaryl group, or (ii) a nitrogen-containing heterocyclic group, and wherein the group attached to the terminal nitrogen atom of the urea group is a 6-membered cyclic group substituted at the 2- and 4-positions. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP.sub.3inhibition.

##STR00001##

The present invention relates to compounds of formula (I): wherein Q is O or S; R.sup.1 is a cyclic group substituted with at least one group X, wherein R.sup.1 may optionally be further substituted; X is any group comprising a carbonyl group; and R.sup.2 is a cyclic group substituted at the α-position, wherein R.sup.2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the dual action of NLRP.sub.3 inhibition and the stimulation of insulin secretion. ##STR00001##

The present invention relates to compounds of formula (I): wherein Q is O or S; R.sup.1 is a cyclic group substituted with at least one group X, wherein R.sup.1 may optionally be further substituted; X is any group comprising a carbonyl group; and R.sup.2 is a cyclic group substituted at the α-position, wherein R.sup.2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the dual action of NLRP.sub.3 inhibition and the stimulation of insulin secretion. ##STR00001##

The present invention relates to phenylsulfonylureas and phenylsulfonylthioureas, wherein the phenyl ring is substituted either (i) at the ortho-position with a halo group, or (ii) at the meta- and para-positions, and wherein the group attached to the terminal nitrogen atom of the urea group is a 6-membered cyclic group substituted across the 2,3-positions with a fused ring and further substituted at the 4-position. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP.sub.3 inhibition.

##STR00001##

The present invention relates to phenylsulfonylureas and phenylsulfonylthioureas, wherein the phenyl ring is substituted either (i) at the ortho-position with a halo group, or (ii) at the meta- and para-positions, and wherein the group attached to the terminal nitrogen atom of the urea group is a 6-membered cyclic group substituted across the 2,3-positions with a fused ring and further substituted at the 4-position. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP.sub.3 inhibition.

##STR00001##

The present invention relates to compounds of formula (I): wherein Q is O or S; R.sup.1 is a cyclic group substituted with at least one group X, wherein R.sup.1 may optionally be further substituted; X is any group comprising a carbonyl group; and R.sup.2 is a cyclic group substituted at the -position, wherein R.sup.2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the dual action of NLRP.sub.3 inhibition and the stimulation of insulin secretion.

##STR00001##

The present invention relates to compounds of formula (I): wherein Q is O or S; R.sup.1 is a cyclic group substituted with at least one group X, wherein R.sup.1 may optionally be further substituted; X is any group comprising a carbonyl group; and R.sup.2 is a cyclic group substituted at the -position, wherein R.sup.2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the dual action of NLRP.sub.3 inhibition and the stimulation of insulin secretion.

##STR00001##

The invention relates to a color developer of formula (I), (Ar.sup.1SO.sub.2NH-)m-Y(NHC(O)NHSO.sub.2Ar.sub.2)n (I), wherein Ar.sup.1 is an unsubstituted or substituted aromatic moiety, Ar.sup.2 is an unsubstituted or substituted phenyl moiety, Y is at least an (m+n)-times substituted benzene group or naphthalene group, and Y is substituted in such a way that at least one Ar.sub.2SO.sub.2NHC(O)NH group is in ortho-position with respect to at least one Ar.sup.1SO.sub.2NH group. The invention further relates to a heat-sensitive recording material, comprising a carrier substrate and a heat-sensitive color-forming layer, which contains at least one color former and at least one phenol-free color developer, the at least one color developer being the compound of formula (I). The invention further relates to a method for producing said heat-sensitive recording material.

The invention relates to a color developer of formula (I), (Ar.sup.1SO.sub.2NH-)m-Y(NHC(O)NHSO.sub.2Ar.sub.2)n (I), wherein Ar.sup.1 is an unsubstituted or substituted aromatic moiety, Ar.sup.2 is an unsubstituted or substituted phenyl moiety, Y is at least an (m+n)-times substituted benzene group or naphthalene group, and Y is substituted in such a way that at least one Ar.sub.2SO.sub.2NHC(O)NH group is in ortho-position with respect to at least one Ar.sup.1SO.sub.2NH group. The invention further relates to a heat-sensitive recording material, comprising a carrier substrate and a heat-sensitive color-forming layer, which contains at least one color former and at least one phenol-free color developer, the at least one color developer being the compound of formula (I). The invention further relates to a method for producing said heat-sensitive recording material.

The invention relates to a color developer of formula (I), (Ar.sup.1SO.sub.2NH)m-Y(NHC(O)NHSO.sub.2Ar.sub.2)n (I), wherein Ar.sup.1 is an unsubstituted or substituted aromatic moiety, Ar.sup.2 is an unsubstituted or substituted phenyl moiety, Y is at least an (m+n)-times substituted benzene group or naphthalene group, and Y is substituted in such a way that at least one Ar.sub.2SO.sub.2NHC(O)NH group is in ortho-position with respect to at least one Ar.sup.1SO.sub.2NH group. The invention further relates to a heat-sensitive recording material, comprising a carrier substrate and a heat-sensitive color-forming layer, which contains at least one color former and at least one phenol-free color developer, the at least one color developer being the compound of formula (I). The invention further relates to a method for producing said heat-sensitive recording material.